Increased serum interleukin-6 and tumor necrosis factor alpha levels in fabry disease: correlation with disease burden
Clinics
; 76: e2643, 2021. graf
Article
en En
| LILACS
| ID: biblio-1286081
Biblioteca responsable:
BR1.1
ABSTRACT
OBJECTIVES:
Fabry disease (FD) is an X-linked lysosomal disease caused by variants of the GLA gene; the formation of defective alpha-galactosidase A contributes to the accumulation of substrates in several organs. Chronic inflammation is thought to contribute to organ damage in FD patients.METHODS:
In total, 36 classic FD patients (15 men/21 women) and 25 healthy controls (20 men/8 women) were assessed. The Mainz Severity Score Index (MSSI) was established after conducting interviews with the patients and chart review. Serum IL-6, IL-1β, and TNF-α levels were evaluated in both groups.RESULTS:
The mean age (years) for FD patients was 43.1±15.4 and that for the controls was 47.4±12.2 (p>0.05). Twenty-two patients (59.5%) were treated with enzyme replacement therapy (ERT). Serum IL-6 and TNF-α levels were significantly higher in FD patients than in the controls. Patients treated with ERT had higher serum IL-6 and TNF-α levels than those not treated with ERT. There was no difference in the serum IL-1β levels between patients treated with ERT and those who were not. The MSSI scores in the patients were correlated with serum levels of IL-6 (r=0.60, p<0.001) and TNF-α (r=0.45, p<0.001).CONCLUSION:
FD was associated with elevated serum levels of IL-6 and TNF-α in this cohort. The FD patients treated with ERT, particularly, women, exhibited higher levels of serum IL-6 and TNF-α than those not treated with ERT; the serum IL-6 and TNF-α levels were correlated with the MSSI scores reflecting greater disease burden.Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Factor de Necrosis Tumoral alfa
/
Enfermedad de Fabry
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clinics
Asunto de la revista:
MEDICINA
Año:
2021
Tipo del documento:
Article